carvedilol has been researched along with ramipril in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 10 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bellini, MA; Boschi, L; Forconi, S; Guerrini, M; Pallassini, A; Postorino, G; Richichi, MG; Trabalzini, L; Turchetti, V | 1 |
| Cohen-Solal, A; Dietz, R; Eichhorn, E; Erhardt, L; Hobbs, FD; Krum, H; Maggioni, A; McKelvie, RS; McMurray, J; Piña, IL; Soler-Soler, J; Swedberg, K | 1 |
| Shapiro, R; Thai, NL | 1 |
| Akdag, I; Arabul, M; Dilek, K; Ersoy, A; Gullulu, M; Kahvecioglu, S; Yavuz, M; Yurtkuran, M | 1 |
| Dabrowski, R; Pedzich-Placha, E | 1 |
| Abdullaev, AA; Gafurova, RM; Islamova, UA; Kadieva, IA; Mutalipov, KhM | 1 |
| Akpek, M; Kaya, EG; Kaya, MG; Lam, YY; Sarli, B; Topsakal, R | 1 |
| Ranawaka, H; Shyamali, NL | 1 |
| Benck, U; Diehl, S; Krämer, BK; Mircheva, M; Rathmann, N | 1 |
| Franken, PR; Woltersdorf, R | 1 |
| Choi, D; Hong, MK; Jung, S; Kim, BK; Kim, SH; Park, SM | 1 |
1 review(s) available for carvedilol and ramipril
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 trial(s) available for carvedilol and ramipril
| Article | Year |
|---|---|
Comparison of higher dose of losartan treatment with losartan plus carvedilol and losartan plus ramipril in patients with glomerulonephritis and proteinuria.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Carbazoles; Carvedilol; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Glomerulonephritis; Humans; Losartan; Propanolamines; Proteinuria; Ramipril; Treatment Outcome; Vasodilator Agents | 2007 |
[Efficacy of ramipril, carvedilol, and trimetazidine MR in improvement of quality of life of patients after myocardial infarction].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Drug Therapy, Combination; Echocardiography; Electrocardiography; Follow-Up Studies; Humans; Myocardial Infarction; Propanolamines; Quality of Life; Ramipril; Retrospective Studies; Time Factors; Treatment Outcome; Trimetazidine; Vasodilator Agents | 2010 |
Tenascin-C as predictor of left ventricular remodeling and mortality in patients with dilated cardiomyopathy.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Drug Therapy, Combination; Echocardiography; Female; Furosemide; Heart Function Tests; Hong Kong; Humans; Male; Predictive Value of Tests; Prognosis; Propanolamines; Ramipril; Spironolactone; Survival Rate; Tenascin; Tetrazoles; Turkey; Ventricular Remodeling | 2013 |
11 other study(ies) available for carvedilol and ramipril
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Haemorheological and endothelial-dependent alterations in heart failure after ACE inhibitor, calcium antagonist and beta blocker.
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Arginine; Blood Viscosity; Calcium; Carbazoles; Carvedilol; Citrulline; Erythrocytes; Female; Fibrinogen; Heart Failure; Humans; Male; Middle Aged; Nitric Oxide Synthase; Propanolamines; Ramipril; Time Factors; Treatment Outcome; Vascular Cell Adhesion Molecule-1; Vasodilator Agents | 2002 |
Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzopyrans; Biphenyl Compounds; Bisoprolol; Captopril; Carbazoles; Carvedilol; Drug Therapy, Combination; Enalapril; Ethanolamines; Evidence-Based Medicine; Guideline Adherence; Heart Failure; Humans; Indoles; Lisinopril; Metoprolol; Mineralocorticoid Receptor Antagonists; Nebivolol; Practice Guidelines as Topic; Propanolamines; Ramipril; Spironolactone; Stroke Volume; Tetrazoles; Valine; Valsartan | 2005 |
Oxidative stress: a potentially important new marker in renal transplantation.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Gene Expression; Heme Oxygenase-1; Humans; Hypertension; Kidney Transplantation; NADPH Oxidases; Oxidative Stress; Propanolamines; Ramipril | 2006 |
[Improvement of left ventricular function during combined carvedilol, ramipril and spironolactone therapy after myocarditis in patient treated earlier by chemotherapy due to Hodgkin's lymphoma - 3-years follow-up].
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Drug Therapy, Combination; Female; Follow-Up Studies; Hodgkin Disease; Humans; Mineralocorticoid Receptor Antagonists; Myocarditis; Propanolamines; Ramipril; Spironolactone; Ventricular Dysfunction, Left; Ventricular Function, Left | 2010 |
Takotsubo cardiomyopathy after an emotional outburst.
Topics: Antihypertensive Agents; Aspirin; Carbazoles; Carvedilol; Diuretics; Echocardiography; Family Conflict; Female; Furosemide; Humans; Middle Aged; Platelet Aggregation Inhibitors; Propanolamines; Ramipril; Takotsubo Cardiomyopathy; Ventricular Dysfunction, Left | 2015 |
[A 93-year-old patient with hypertensive crises and renal failure due to bilateral renal artery stenosis].
Topics: Aged, 80 and over; Angioplasty; Carbazoles; Carvedilol; Combined Modality Therapy; Diagnosis, Differential; Drug Therapy, Combination; Female; Humans; Hypertension; Hypertension, Renovascular; Life Style; Propanolamines; Ramipril; Renal Artery Obstruction; Stents; Weight Loss | 2015 |
Risk of renal dysfunction in an elderly patient with chronic heart failure.
Topics: Aged, 80 and over; Atrial Fibrillation; Carbazoles; Carvedilol; Diclofenac; Digoxin; Drug Interactions; Drug Therapy, Combination; Female; Heart Failure; Humans; Hypertension; Kidney Failure, Chronic; Myocardial Infarction; Potassium; Potentially Inappropriate Medication List; Propanolamines; Ramipril; Risk Factors; Spironolactone | 2016 |
Comparison of Efficacy between Ramipril and Carvedilol on Limiting the Expansion of Abdominal Aortic Aneurysm in Mouse Model.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Aortic Aneurysm, Abdominal; Carvedilol; Disease Models, Animal; Male; Mice; Mice, Inbred C57BL; Ramipril; Random Allocation | 2019 |